Marcadores de fibrosis hepática-Reference-Cited by-同舟云学术

Marcadores de fibrosis hepática

Published:2018-04 Issue:8 Volume:150 Page:310-316
ISSN:0025-7753
Container-title:Medicina Clínica
language:es
Short-container-title:Medicina Clínica

Author:

Caballería Llorenç,Torán Pere,Caballería Joan

Publisher

Elsevier BV

Subject

General Medicine

Reference60 articles.

1. EASL recommendations on treatment of hepatitis C 2015;J Hepatol.,2015

2. AASLD guidelines for treatment of chronic hepatitis B;Terrault;Hepatology.,2016

3. World Health Organization. Global status report on alcohol and health 2014 [consultado 19 Sep 2015]. Disponible en: http://www.who.int/substance_abuse/publications/global_alcohol_report/en/

4. EASL clinical practice guidelines: Management of alcoholic liver disease;J Hepatol.,2012

5. Global epidemiology of nonalcoholic fatty liver disease — Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology.,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum N-Glycan Markers for Diagnosing Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels;Engineering;2023-07

2. Correlación de la cuantificación de fibrosis hepática por morfometría mediante HepaScan con el análisis de las biopsias hepáticas. Estudio piloto;Gaceta Médica de México;2023-04-03

3. Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2023-04

4. Role of follistatin-like protein 1 in liver diseases;Experimental Biology and Medicine;2022-12-19

5. Role of Oxidative Stress and Lipid Peroxidation in the Pathophysiology of NAFLD;Antioxidants;2022-11-10